Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05473910 · ClinicalTrials.gov registry record · Phase 1

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

A Phase 1 study of Myelodysplastic Syndromes and AML, sponsored by TScan Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
75
Enrollment target
15
Study locations

NCT05473910 is a Phase 1 study of Myelodysplastic Syndromes and AML that is actively recruiting participants, run by TScan Therapeutics. The registered enrollment target is 75 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (74% lower). The trial reports 15 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05473910, a Phase 1 study of Myelodysplastic Syndromes and AML, is actively recruiting participants, sponsored by TScan Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
75 participants
Enrollment target
15
Study locations

Study Summary

This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD

Conditions Studied

Myelodysplastic Syndromes AML ALL, Adult

Interventions

  • OTHER Control
  • DRUG SOC + TSC-100
  • DRUG SOC + TSC-101

Study Locations (15)

New York

  • Columbia University - New York
  • Mount Sinai - New York

Texas

  • Baylor University Medical Center - Dallas
  • MD Anderson - Houston

California

  • City of Hope - Duarte

Connecticut

  • Yale - New Haven

Florida

  • Memorial Healthcare System - Hollywood

Georgia

  • Northside Hospital - Atlanta

Maryland

  • John Hopkins University - Baltimore

Massachusetts

  • Mass General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2022-11-01
Est. Completion 2026-06
Phase Phase 1

Sponsor

TScan Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05473910

The ClinicalTrials.gov registry entry for NCT05473910 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (74% lower). The listed sponsor is TScan Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 3 interventions - of which Control is the first listed.

NCT05473910 reports 15 study locations spanning 13 distinct geographic areas - top geographies include New York, Texas, California.

Frequently Asked Questions

What is clinical trial NCT05473910 about?

NCT05473910 is a clinical study titled "A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation". This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AM...

What is the current status of trial NCT05473910?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2022-11-01. Estimated completion is 2026-06.

What conditions does trial NCT05473910 study?

This clinical trial studies the following conditions: Myelodysplastic Syndromes, AML, ALL, Adult.

What interventions are being tested in trial NCT05473910?

The interventions under investigation include: Control (OTHER), SOC + TSC-100 (DRUG), SOC + TSC-101 (DRUG).

Who is sponsoring clinical trial NCT05473910?

This trial is sponsored by TScan Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05473910 being conducted?

This trial has 15 study locations across California, Connecticut, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelodysplastic Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelodysplastic Syndromes

All registered trials for this condition

AML

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.